Brokerage firm Jefferies Maintains its rating on BioMarin Pharmaceutical(NASDAQ:BMRN). In a research note issued to the investors, the brokerage major Raises the price-target to $120.00 per share. The shares have been rated Buy. The rating by Jefferies was issued on Aug 5, 2016.
In a different note, On Aug 5, 2016, Barclays said it Maintains its rating on BioMarin Pharmaceutical. In the research note, the firm Raises the price-target to $105.00 per share. The shares have been rated ‘Overweight’ by the firm.
BioMarin Pharmaceutical (BMRN) made into the market gainers list on Wednesdays trading session with the shares advancing 1.70% or 1.56 points. Due to strong positive momentum, the stock ended at $93.3, which is also near the day’s high of $94.06. The stock began the session at $92.14 and the volume stood at 14,99,346 shares. The 52-week high of the shares is $140.68 and the 52 week low is $62.12. The company has a current market capitalization of $15,251 M and it has 16,34,65,820 shares in outstanding.
BioMarin Pharmaceutical(BMRN) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $300.13M. Analysts had an estimated revenue of $277.99M. Earnings per share were $-0.26. Analysts had estimated an EPS of $-0.51.
Several Insider Transactions has been reported to the SEC. On Aug 3, 2016, Daniel K Spiegelman (EVP, Chief Financial Officer) sold 4,000 shares at $99.33 per share price.Also, On Aug 3, 2016, George Eric Davis (EVP, General Counsel) sold 2,167 shares at $100.00 per share price.On Aug 3, 2016, Brian Mueller (VP, Corporate Controller) sold 287 shares at $100.00 per share price, according to the Form-4 filing with the securities and exchange commission.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha) Naglazyme (galsulfase) Kuvan (sapropterin dihydrochloride) Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States the European Union. Aldurazyme which was developed in collaboration with Genzyme Corporation (Genzyme) was approved for marketing in the United States the European Union and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).